Abstract 367P
Background
Aumolertinib has shown efficacy in EGFR-mutant NSCLC patients with brain metastases in the phase III AENEAS study. ACHIEVE (NCT04808752) is an ongoing multicenter, open-label, single-arm study evaluating high-dose (165mg) third-generation EGFR-TKI aumolertinib (formerly almonertinib; HS-10296) as first-line therapy in EGFR-mutant NSCLC patients with brain metastases. Here we report primary data from ACHIEVE.
Methods
Treatment-naïve EGFR-mutant NSCLC patients with asymptomatic brain metastases received aumolertinib 165mg orally once daily. Endpoints included progression free survival (PFS), objective response rate (ORR), disease control rate (DCR), CNS ORR and CNS DCR by RECIST v1.1.
Results
At data cut-off (July 4, 2022), 22 patients were included in the analysis. Median age was 61 years (range, 48-75 years), 63.6% were female, and all patients had measurable CNS lesions on baseline brain scan. Efficacy outcomes are summarized in the table. The overall ORR was 90.9% (20/22; 95% CI: 70.8-98.9). The CNS ORR was 86.3 (19/22; 95% CI: 65.1-97.1). The overall and CNS DCR were both 100%. 5 patients experienced blood creatine phosphokinase (CPK) increased, and the ORR was 100% (5/5) and 88.2% (15/17; 95% CI: 63.6-98.9) for patients with or without CPK increased, respectively. PFS data was immature. The safety profile of aumolertinib was consistent with previous reports. Table: 367P
| Overalla | CNSb | |||
| All (N=22) | CPK increased – Yes (n=5) | CPK increased – No (n=17) | All (N=22) | |
| ORR, % (95% CI) | 90.9 (70.8, 98.9) | 100.0 | 88.2 (63.6, 98.5) | 86.3 (65.1, 97.1) |
| CR, No. (%) | 0 | 0 | 0 | 1 (4.5) |
| PR, No. (%) | 20 (90.9) | 5 (100.0) | 15 (88.2) | 18 (81.8) |
| SD, No. (%) | 2 (9.0) | 0 | 2 (11.8) | 3 (13.6) |
| PD, No. (%) | 0 | 0 | 0 | 0 |
| DCR, % (95% CI) | 100.0 | 100.0 | 100.0 | 100.0 |
Data cutoff date: July 4, 2022.aEvaluable for response analysis set. Overall response is derived by combining the CNS and non-CNS lesion time point responses.bEvaluable for measurable CNS response analysis set.
Conclusions
Aumolertinib showed preliminary efficacy at 165 mg once daily as first-line therapy in EGFR-mutant NSCLC patients with brain metastases. Enrollment for the trial will continue.
Clinical trial identification
NCT04808752.
Editorial acknowledgement
Legal entity responsible for the study
Zhejiang Cancer Hospital.
Funding
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
364P - Tepotinib with an EGFR-tyrosine kinase inhibitor (TKI) in patients with EGFR-mutant MET-amplified NSCLC: A case series
Presenter: Azura Ahmad
Session: Poster viewing 05.
365P - Patterns of progression on first-line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study
Presenter: Alexandra Schuler
Session: Poster viewing 05.
366P - EGFR amplification is a putative resistance mechanism for NSCLC-LM patients with TKI therapy and is associated with poor outcome
Presenter: Hainan Yang
Session: Poster viewing 05.
368P - A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs
Presenter: Zhen-Bang Gu
Session: Poster viewing 05.
370P - Outcomes in patients with EGFR-mutant locally advanced or metastatic NSCLC co-mutations receiving aumolertinib as first-line treatment: A retrospective study
Presenter: Fang Cun
Session: Poster viewing 05.
371P - Real-world data of first-line treatment with aumolertinib for elderly EGFR+ NSCLC patients
Presenter: Haitao Zhang
Session: Poster viewing 05.
373P - Safety and efficacy of aumolertinib treatment in patients with advanced NSCLC harboring uncommon EGFR mutations: Cohort 2
Presenter: WenFeng Fang
Session: Poster viewing 05.